Pharmacogenetics and adverse drug reactions

被引:387
作者
Meyer, UA [1 ]
机构
[1] Univ Basel, Biozentrum, Div Pharmacol Neurobiol, CH-4056 Basel, Switzerland
关键词
D O I
10.1016/S0140-6736(00)03167-6
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Polymorphisms in the genes that code for drug-metabolising enzymes, drug transporters, drug receptors, and ion channels can affect an individual's risk of having an adverse drug reaction, or can alter the efficacy of drug treatment in that individual. Mutant alleles at a single gene locus are the best studied individual risk factors for adverse drug reactions, and include many genes coding for drug-metabolising enzymes. These genetic polymorphisms of drug metabolism produce the phenotypes of "poor metabolisers" or "ultrarapid metabolisers" of numerous drugs. Together, such phenotypes make up a substantial proportion of the population. Pharmacogenomic techniques allow efficient analysis of these risk factors, and genotyping tests have the potential to optimise drug therapy in the future.
引用
收藏
页码:1667 / 1671
页数:5
相关论文
共 28 条
  • [1] Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications
    Aithal, GP
    Day, CP
    Kesteven, PJL
    Daly, AK
    [J]. LANCET, 1999, 353 (9154) : 717 - 719
  • [2] Meta-analysis of studies on genetic variation in 5-HT2A receptors and clozapine response
    Arranz, MJ
    Munro, J
    Sham, P
    Kirov, G
    Murray, RM
    Collier, DA
    Kerwin, RS
    [J]. SCHIZOPHRENIA RESEARCH, 1998, 32 (02) : 93 - 99
  • [3] Bertilsson L, 1997, ACTA PSYCHIAT SCAND, V96, P14
  • [4] The essence of SNPs
    Brookes, AJ
    [J]. GENE, 1999, 234 (02) : 177 - 186
  • [5] Extension of a pilot study: Impact from the cytochrome P450 2D6 polymorphism on outcome and costs associated with severe mental illness
    Chou, WH
    Yan, FX
    de Leon, J
    Barnhill, J
    Rogers, T
    Cronin, M
    Pho, M
    Xiao, V
    Ryder, TB
    Liu, WW
    Teiling, C
    Wedlund, PJ
    [J]. JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2000, 20 (02) : 246 - 251
  • [6] 10-hydroxylation of nortriptyline in white persons with 0, 1, 2, 3, and 13 functional CΥP2D6 genes
    Dalén, P
    Dahl, ML
    Ruiz, MLB
    Nordin, J
    Bertilsson, L
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1998, 63 (04) : 444 - 452
  • [7] The role of innovation in drug development
    Drews, J
    Ryser, S
    [J]. NATURE BIOTECHNOLOGY, 1997, 15 (13) : 1318 - 1319
  • [8] Pharmacogenomics: Translating functional genomics into rational therapeutics
    Evans, WE
    Relling, MV
    [J]. SCIENCE, 1999, 286 (5439) : 487 - 491
  • [9] Effects of clarithromycin on the metabolism of omeprazole in relation to CYP2C19 genotype status in humans
    Furuta, T
    Ohashi, K
    Kobayashi, K
    Iida, I
    Yoshida, H
    Shirai, N
    Takashima, M
    Kosuge, K
    Hanai, H
    Chiba, K
    Ishizaki, T
    Kaneko, E
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1999, 66 (03) : 265 - 274
  • [10] CHARACTERIZATION OF THE COMMON GENETIC-DEFECT IN HUMANS DEFICIENT IN DEBRISOQUINE METABOLISM
    GONZALEZ, FJ
    SKODA, RC
    KIMURA, S
    UMENO, M
    ZANGER, UM
    NEBERT, DW
    GELBOIN, HV
    HARDWICK, JP
    MEYER, UA
    [J]. NATURE, 1988, 331 (6155) : 442 - 446